from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A drug under investigation for the acute conversion of atrial fibrillation.


Sorry, no etymologies found.


  • In April, Merck signed a separate licensing agreement with Cardiome Pharma Corp., of Canada, to develop a drug called vernakalant to treat the rhythm condition.

    Merck Acquires Rights to Anticoagulant

  • COM. TO) hopes to see vernakalant, which is used for the treatment of atrial fibrillation, receive regulatory approval.

    Reuters: Top News

  • Canadian pharmaceutical maker Cardiome Pharma rose 79 cents, or 25%, to 3.97 after signing a license agreement with Merck for vernakalant, a candidate for treating atrial fibrillation, or abnormal heart rhythm.

    REITs Colonial Properties, Diamondrock Surge

  • Cardiome Pharma jumped 2.03, or 24%, to 10.37, as the Vancouver cardiac-drug company released positive final results from its Phase IIb trial of vernakalant, an oral treatment for atrial fibrillation, or abnormal heartbeat.

    IndyMac, Anchor Bancorp Lead

  • The drug is currently being developed for two potential applications: (1) vernakalant (IV) is being evaluated as a potential candidate to terminate an atrial fibrillation episode and return the heart to normal rhythm; and (2) vernakalant (oral) is being evaluated as an oral maintenance therapy for the long-term prevention of atrial fibrillation recurrence.

  • We would like to thank Astellas for their many contributions to this program and we look forward to working with Merck to restart the advancement of vernakalant IV in North America. said Doug Janzen, Chief Executive Officer of Cardiome.

  • Merck, known as MSD outside the US and Canada, also has exclusive global rights to the oral formulation of vernakalant vernakalant oral which is being studied for the maintenance of normal heart rhythm in patients with atrial fibrillation.

  • Merck now holds exclusive global rights to the intravenous (IV) formulation of vernakalant (vernakalant IV) for rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

  • We are pleased that Merck has taken steps to acquire global development and commercialization rights to vernakalant IV.

  • Patients with a history of CHF showed a higher incidence of ventricular arrhythmia in the first two hours post dose (7.3 percent for vernakalant compared to 1.6 percent in placebo).

    WebWire | Recent Headlines


Log in or sign up to get involved in the conversation. It's quick and easy.